Aegerion Pharmaceuticals
AEGR
AEGR was delisted on the 29th of November, 2016.
109 hedge funds and large institutions have $1.18B invested in Aegerion Pharmaceuticals in 2015 Q4 according to their latest regulatory filings, with 29 funds opening new positions, 36 increasing their positions, 25 reducing their positions, and 16 closing their positions.
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
81% more first-time investments, than exits
New positions opened: 29 | Existing positions closed: 16
44% more repeat investments, than reductions
Existing positions increased: 36 | Existing positions reduced: 25
37% more call options, than puts
Call options by funds: $15.7M | Put options by funds: $11.5M
14% more capital invested
Capital invested by funds: $1.03B → $1.18B (+$147M)
14% more funds holding
Funds holding: 96 → 109 (+13)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
AC
Armistice Capital
New York
|
+$14.5M |
| 2 |
BC
Broadfin Capital
New York
|
+$14.3M |
| 3 |
State Street
Boston,
Massachusetts
|
+$5.1M |
| 4 |
OAM
Oxford Asset Management
Oxford,
United Kingdom
|
+$4.89M |
| 5 |
BIM
Bogle Investment Management
Newton Lower Falls,
Massachusetts
|
+$3.99M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
NTC
North Tide Capital
Boston,
Massachusetts
|
-$12.5M |
| 2 |
PI
Putnam Investments
Boston,
Massachusetts
|
-$5.88M |
| 3 |
GTC
Ghost Tree Capital
New York
|
-$3.4M |
| 4 |
Morgan Stanley
New York
|
-$3.08M |
| 5 |
CS
Credit Suisse
Zurich,
Switzerland
|
-$3.05M |
AEGR Hedge Fund Activity: Q4 2015 in Review
109 of the 3,812 institutional investors tracked by Wall St. Rank reported a position in Aegerion Pharmaceuticals (AEGR) for Q4 2015, worth a combined $1.18B — up 14% from $1.03B a quarter earlier.
Buyers outnumbered sellers: 29 funds opened new AEGR positions and 16 closed out — a net gain of 13 holders — while 36 added to existing stakes and 25 trimmed.
The largest buyer was Armistice Capital, opening a new position worth an estimated $14.5M. The largest seller was North Tide Capital, exiting entirely with an estimated $12.5M sold.
- 109 institutional investors held Aegerion Pharmaceuticals (AEGR) as of Q4 2015, up from 96 in Q3 2015.
- Funds reported $1.18B of Aegerion Pharmaceuticals stock for Q4 2015, up 14% quarter-over-quarter.
- 29 funds opened new Aegerion Pharmaceuticals positions in Q4 2015 and 16 closed out, a net change of +13 holders.
- The largest Aegerion Pharmaceuticals buyer in Q4 2015 was Armistice Capital, an estimated $14.5M added.
- The largest Aegerion Pharmaceuticals seller in Q4 2015 was North Tide Capital, an estimated $12.5M sold.
Based on aggregated 13F filings for Q4 2015.